Schacter Named Clinical Trials Director at Yale

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 3
Volume 5
Issue 3

NEW HAVEN, Conn--Lee Philip Schacter, PhD, MD, has been named associate director for clinical trials for the Yale Cancer Center. In that role, he will oversee the clinical research projects on experimental cancer treatment taking place at the Center. Dr. Schacter comes to Yale from Bristol-Myers Squibb, where he was a director of the clinical cancer research program.

NEW HAVEN, Conn--Lee Philip Schacter, PhD, MD, has been namedassociate director for clinical trials for the Yale Cancer Center.In that role, he will oversee the clinical research projects onexperimental cancer treatment taking place at the Center. Dr.Schacter comes to Yale from Bristol-Myers Squibb, where he wasa director of the clinical cancer research program.

His top priority in his new position will be to further developmentof the Center's new clinical research program. "We have mostof the people in place," he said, referring to the Center'scorps of research scientists and physicians. "And we havepromising experimental treatment programs underway. That combinationmakes this a place people look to for progressive cancer therapy."

Dr. Schacter will also be instrumental in building a network forcommunity-based clinical research. The effort will involve extendingresearch projects to community hospitals throughout Connecticutas well as physicians' offices.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Related Content